Source: Annual Congress 2004 - Clinical and behavioural consequences of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. K. C. Lee, B. J. Lipworth (Dundee, United Kingdom). Alveolar absorption and systemic bioactivity of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Eur Respir J 2004; 24: Suppl. 48, 205

Member's Comments

No comment yet.

Related content which might interest you: Inhaled budesonide in the management of chronic obstructive pulmonary diseases Source: Eur Respir J 2002; 20: Suppl. 38, 244s Year: 2002 Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 1075 Year: 2004 The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007 Acute protective effect of inhaled fluticasone on airway hyperresponsiveness to adenosine 5’-monophosphate in asthma but not in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 442s Year: 2004 Inhaled corticosteroids and survival in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 202-203 Year: 2003 Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002 Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 602s Year: 2004 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003 Effects of inhaled corticosteroids on airway inflammations of different types in patients with chronic obstructive pulmonary disease or asthma in stable phase Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001 Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Source: Eur Respir J 2003; 21: 260-266 Year: 2003 Inhaled corticosteroids and hospitalisation due to exacerbation of COPD Source: Eur Respir J 2003; 22: 286-289 Year: 2003 Triple therapy with Fluticasone furoate/Umeclidinium/Vilanterol compared with dual bronchodilation or triple therapy with inhaled corticosteroids/dual bronchodilation in patients with chronic obstructive pulmonary disease Source: Virtual Congress 2020 – Investigations of COPD Year: 2020 Dose response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Dose–response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Eur Respir J 2011; 37: 206-209 Year: 2011 Effects of fluticasone and ciclesonide on pulmonary function and airway inflammation in stable mild asthmatics Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 Efficiency of nebulised magnesium sulphate in exacerbations of chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 214s Year: 2006